Latigo Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in the development of non-opioid pain medicines. Based in Thousand Oaks, CA, the company leverages advanced technologies, including artificial intelligence and machine learning, to create innovative treatments that address the unmet needs in pain management.
LTG-001 is Latigo Biotherapeutics' lead candidate that aims to provide effective non-opioid pain relief. Successfully navigating Phase 1 clinical trials, it addresses the root causes of pain without the associated risks of addiction linked to opioid medications.
LTG-001 solves the critical problem of finding effective pain treatment for patients at risk of opioid dependency, providing a safer alternative with fewer side effects.
The need for effective pain relief without the high risks of addiction associated with opioids and the gastrointestinal issues stemming from NSAIDs.